ArticleChemical & biomedical imaging2023
NAD(P)H Activated Fluorescent Probe for Rapid Intraoperative Pathological Diagnosis and Tumor Histological Grading.
Article in Chemical & biomedical imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Lipid Metabolism-Related Rapid Pathological Diagnosis and Staging of Breast Tissue Sections Using Two-Photon Fluorescence Imaging Assisted with a Carbonized Polymer Dot Probe.Chemical & biomedical imaging · 2026Article
- A NIR fluorotag reporter CETIF6a enables bright pan-tumor labeling and functional proteomic profiling.Nature communications · 2026Article
- A Sensor-Oriented Multimodal Medical Data Acquisition and Modeling Framework for Tumor Grading and Treatment Response Analysis.Sensors (Basel, Switzerland) · 2026Article
- A Quinolinium-Functionalized Hemicyanine Dye for Ratiometric NAD(P)H Sensing in Live Cells, Kidney Tissues, and Drosophila melanogaster.Sensors and actuators. B, Chemical · 2025Article
- Harnessing Biomarker Activatable Probes for Early Stratification and Timely Assessment of Therapeutic Efficacy in Cancer.Exploration (Beijing, China) · 2025Review
- Rapid sorting and auxiliary evaluation of malignant breast tumors by accurate imaging analysis of metastasis-related biomarker.Science advances · 2025Article
- Pre-clinical study of IR808 dye for cervical cancer in vitro and in vivo imaging.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- A NIR Dual-Channel Fluorescent Probe for Fluctuations of Intracellular Polarity and HChemical & biomedical imaging · 2024Article
- Near-Infrared Fluorescent Probe with pH- and Viscosity-Switchable Performance for the Detection of Thrombi in Live Animals and Organs.Chemical & biomedical imaging · 2024Article
- Non-invasive diagnosis of bacterial and non-bacterial inflammations using a dual-enzyme-responsive fluorescent indicator.Chemical science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapid and accurate intraoperative pathological diagnosis (IOPD) is essential for intraoperative decision-making to improve patients' outcomes and avoid reoperations. In this study, using a NAD(P)H-activated fluorescent probe, a multifunctional fluorescent indicator has been developed to selectively identify tumor cells from normal tissue and to achieve cancer grading identification. This rapid response probe, CyQ-1, features unprecedented sensitivity and rapid response toward NADH at low nanomolar levels under physiological conditions. Moreover, this indicator allows both colorimetric and fluorescent NADH detection in HeLa, A549, MDA-MB-231, 4T1, MCF-7, HePG2, HUVEC, and HL-7702 cells. Expanding the use of this indicator to advanced tissue models, its ability to visualize NADH in 120 paraffin-embedded colorectal sections and 20 cases of intraoperative frozen sections of lung cancer was further verified. CyQ-1-based cancer grading identification shows an overall 92.5 and 100% agreement with the "gold standard test" of histologic grading toward paraffin and frozen sections, respectively. The sensitivity and specificity for discriminating poorly, moderately, and well-differentiated tumor sections were all above 90%. In a word, the rapid and accurate NADH detection ability for clinical sections makes this proposed indicator a potential candidate for clinical IOPD quantification and tumor differentiation grade recognition.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.